Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 16,928 Shares

by · The Markets Daily

Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) insider Los Pinos Elisabet De sold 16,928 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $4.86, for a total value of $82,270.08. Following the completion of the sale, the insider directly owned 457,463 shares in the company, valued at $2,223,270.18. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

  • On Wednesday, October 29th, Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock. The shares were sold at an average price of $6.35, for a total transaction of $57,461.15.

Aura Biosciences Trading Down 1.0%

Shares of Aura Biosciences stock traded down $0.05 during trading hours on Tuesday, reaching $4.97. 217,669 shares of the company’s stock were exchanged, compared to its average volume of 164,885. The company has a fifty day moving average of $5.74 and a 200-day moving average of $6.13. Aura Biosciences, Inc. has a 52-week low of $4.34 and a 52-week high of $8.27.

Aura Biosciences (NASDAQ:AURA – Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. Analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on AURA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 29th. Evercore ISI assumed coverage on Aura Biosciences in a report on Tuesday, November 25th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Check Out Our Latest Analysis on AURA

Hedge Funds Weigh In On Aura Biosciences

Several hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. acquired a new stake in Aura Biosciences during the 2nd quarter worth about $31,926,000. Vanguard Group Inc. lifted its stake in Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock worth $17,863,000 after acquiring an additional 413,001 shares in the last quarter. Franklin Resources Inc. boosted its position in Aura Biosciences by 5.9% during the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock worth $14,653,000 after acquiring an additional 130,221 shares during the period. Nantahala Capital Management LLC grew its stake in Aura Biosciences by 67.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock valued at $13,257,000 after acquiring an additional 850,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. increased its holdings in shares of Aura Biosciences by 8.8% in the 3rd quarter. Levin Capital Strategies L.P. now owns 1,627,274 shares of the company’s stock valued at $10,057,000 after purchasing an additional 131,714 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

See Also